全文获取类型
收费全文 | 3975篇 |
免费 | 136篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 108篇 |
妇产科学 | 185篇 |
基础医学 | 503篇 |
口腔科学 | 31篇 |
临床医学 | 236篇 |
内科学 | 1044篇 |
皮肤病学 | 156篇 |
神经病学 | 321篇 |
特种医学 | 99篇 |
外国民族医学 | 1篇 |
外科学 | 534篇 |
综合类 | 9篇 |
预防医学 | 253篇 |
眼科学 | 91篇 |
药学 | 209篇 |
中国医学 | 4篇 |
肿瘤学 | 272篇 |
出版年
2023年 | 6篇 |
2022年 | 8篇 |
2021年 | 24篇 |
2020年 | 22篇 |
2019年 | 23篇 |
2018年 | 19篇 |
2017年 | 18篇 |
2016年 | 24篇 |
2015年 | 34篇 |
2014年 | 42篇 |
2013年 | 56篇 |
2012年 | 223篇 |
2011年 | 289篇 |
2010年 | 97篇 |
2009年 | 100篇 |
2008年 | 387篇 |
2007年 | 408篇 |
2006年 | 408篇 |
2005年 | 385篇 |
2004年 | 337篇 |
2003年 | 352篇 |
2002年 | 237篇 |
2001年 | 61篇 |
2000年 | 64篇 |
1999年 | 38篇 |
1998年 | 30篇 |
1997年 | 32篇 |
1996年 | 21篇 |
1995年 | 12篇 |
1994年 | 17篇 |
1993年 | 17篇 |
1992年 | 32篇 |
1991年 | 31篇 |
1990年 | 32篇 |
1989年 | 25篇 |
1988年 | 24篇 |
1987年 | 31篇 |
1986年 | 24篇 |
1985年 | 15篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 7篇 |
1979年 | 15篇 |
1978年 | 8篇 |
1977年 | 8篇 |
1974年 | 5篇 |
1973年 | 7篇 |
1972年 | 6篇 |
1970年 | 5篇 |
1966年 | 3篇 |
排序方式: 共有4114条查询结果,搜索用时 15 毫秒
51.
Bourreau E Pascalis H Prévot G Kariminia A Jolly N Milon G Buffet P Michel R Meynard JB Boutin JP Aschimoff D Launois P 《Scandinavian journal of immunology》2003,58(2):201-210
A prospective study was undertaken to define early predictive immunological marker(s) of exposure to Leishmania in naïve subjects who have never been exposed to any Leishmania and who were also free of any cutaneous leishmaniasis lesions. These naïve subjects could have been exposed to Leishmania in a rain forest where Leishmania guyanensis and their natural vectors and mammalian host are cocirculating. The production of interferon (IFN)‐γ in response to the Leishmania homologue of the mammalian receptor for activated c kinase (LACK), a candidate for vaccine against leishmaniasis was analysed. At the end of their stay in the rain forest, LACK‐specific CD8+ T cells were detected in subjects whose peripheral blood mononuclear cell (PBMC) produced IFN‐γ in response to soluble Leishmania antigens (SLA) and in those whose PBMC remained unresponsive to SLA. However, LACK‐specific CD4+ T cells were detected only in PBMCs from individuals who became IFN‐γ responders to SLA. In subjects whose PBMC became positive to SLA, LACK‐reactive CD4+ T cells producing high level of IFN‐γ were detectable before the SLA‐reactive IFN‐γ producing CD4+ T cells, suggesting that the former readout assay could be used as an early predictive immunological marker of exposure to Leishmania in subjects who remained disease free. 相似文献
52.
Piette V Bousquet C Kvedariene V Dhivert-Donnadieu H Crampette L Senac JP Bousquet J Demoly P 《Allergy》2004,59(8):863-868
BACKGROUND: Involvement of paranasal sinuses has been suggested in allergic rhinitis but not clearly demonstrated. AIMS: To investigate the relationship between intermittent allergic rhinitis and computerized tomography (CT). METHODS: Twenty patients with intermittent rhinitis and sensitized to cypress pollens underwent unilateral nasal provocation tests (NPTs) using increasing concentrations of cypress pollens out of the pollen season. Sinus CT-scans were carried out just before a NPT and 24 h later. Nasal lavage was carried out just before a NPT, 30 min after a positive challenge and again 24 h later. Leucotriene C4/D4, intracellular adhesion molecule-1 and eosinophil cationic protein were measured in nasal secretions. RESULTS: Thirteen patients (65%) showed an alteration in their CT-scans after allergen challenge. Ten of them showed sinus changes controlateral to their allergenic provocation. Radiological changes mainly affected the osteomeatal complex and the ethmoid sinuses. Pre-existing abnormalities (13 of 20 cases) mainly concerned the maxillary sinuses. There was no correlation between CT-scan abnormalities and levels of mediators released in nasal secretions. CONCLUSIONS: We have shown that nasal allergen challenge can produce radiological changes in the paranasal sinuses. This mainly concerned the ethmoid sinuses. 相似文献
53.
AIMS: The tumour-associated trypsin inhibitor (TATI) is a 6-kDa protease inhibitor with potential inhibitory effects on tissue degradation. In serum, increased levels have been associated with adverse prognosis in different forms of cancer. We assessed the tumour tissue expression and prognostic value of TATI in a surgically treated, single-institution series of patients with gastric cancer. METHODS AND RESULTS: Using a monoclonal anti-TATI antibody, immunohistochemistry was performed on formalin-fixed paraffin-embedded tumour specimens from 336 patients. TATI expression was observed in 265 (79%) of the tumours. There was a significant association between high TATI expression and low stage (P = 0.007), superficial tumours (P = 0.005), and absence of nodal (P = 0.015) and of distant metastases (P = 0.022). In univariate analysis, patients with high TATI expression had a significantly more favourable 5-year cumulative survival compared with patients with negative to moderate immunostaining (43% and 28%, respectively, P = 0.006). On multivariate survival analysis stratified for estimated cure of surgery, stage (P < 0.0001) and age (P = 0.022) at the time of surgery were independent prognostic factors. CONCLUSIONS: High TATI expression in tumour tissue was detected more frequently in patients with early-stage gastric cancer and seems to correlate with a favourable outcome. 相似文献
54.
Bayley JP Baggen JM van der Pouw-Kraan T Crusius JB Huizinga TW Verweij CL 《Tissue antigens》2003,62(2):170-174
Cell trafficking into the rheumatoid synovium is thought to play an important role in the inflammation seen in rheumatoid arthritis. Chemokine receptors play a central role in this process, and several common variants are known, including the CCR2 variant, CCR2-64I, and two variants of the CX3CR1 gene, V249I and T280M. All three variants result in functional amino acid substitutions. We studied the association of these chemokine receptor variants with susceptibility to and severity of rheumatoid arthritis in two Dutch patient populations; 282 consecutive rheumatoid arthritis patients from a rheumatology outpatient clinic, and a cohort of 101 female rheumatoid arthritis patients, followed closely for a 12-year period, from whom hand and feet X-rays taken at three year intervals were scored and analyzed in this study. Although there was a trend towards increased severity of disease in patients carrying CX3CR1 variants, this was not independent of known risk factors. We found no evidence for a significant independent role for the CCR2 and CX3CR1 variants in the susceptibility to or severity of rheumatoid arthritis. 相似文献
55.
Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Journal of medical genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Janssens K Gershoni-Baruch R Van Hul E Brik R Guañabens N Migone N Verbruggen LA Ralston SH Bonduelle M Van Maldergem L Vanhoenacker F Van Hul W 《Journal of medical genetics》2000,37(4):245-249
Camurati-Engelmann disease, progressive diaphyseal dysplasia, or diaphyseal dysplasia Camurati-Engelmann is a rare, autosomal dominantly inherited bone disease, characterised by progressive cortical expansion and sclerosis mainly affecting the diaphyses of the long bones associated with cranial hyperostosis. The main clinical features are severe pain in the legs, muscular weakness, and a waddling gait. The underlying cause of this condition remains unknown.In order to localise the disease causing gene, we performed a linkage study in a large Jewish-Iraqi family with 18 affected subjects in four generations. A genome wide search with highly polymorphic markers showed linkage with several markers at chromosome 19q13. A maximum lod score of 4.9 (theta=0) was obtained with markers D19S425 (58.7 cM, 19q13.1) and D19S900 (67.1 cM, 19q13. 2). The disease causing gene is located in a candidate region of approximately 32 cM, flanked by markers D19S868 (55.9 cM, 19q13.1) and D19S571 (87.7 cM, 19q13.4). 相似文献
56.
Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate
下载免费PDF全文
![点击此处可从《Journal of medical genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
57.
58.
59.
Summary Isolated paralysis of one or both superior oblique muscles in a consecutive series of 43 patients was found to occur most often by indirect injury to the skull.The etiology in the group of spontaneous cases was mostly vascular. With rare exceptions the latter recovered spontaneously. Those with traumatic palsy may be due to contrecoup trauma at the decussation of the nerves or by decompensation of the cerebral fusional mechanism, with dissocation of the images of the two eyes and subsequent vertical deviation.The traumatic cases never recover spontaneously and recession or myectomy of the ipsilateral inferior oblique with or without recession of the contralateral inferior rectus is recommended but only in cases of more than 8 diopters squint, and in cases which do not adapt themselves by minor headtilting.Author's address: University of Antwerpen Universiteitsplein 1 2610 Wilrijk Belgium 相似文献
60.
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. 总被引:4,自引:0,他引:4
K Vera L Djafari S Faivre J-S Guillamo K Djazouli M Osorio F Parker C Cioloca B Abdulkarim J-P Armand E Raymond 《Annals of oncology》2004,15(1):161-171
BACKGROUND: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors. PATIENTS AND METHODS: In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, recommended dose and activity of temozolomide given on days 1-3 and 14-16 every 28 days (one cycle). The starting daily dose was 200 mg/m(2) in a group of at least six patients, with subsequent increments of 50 mg/m(2) in groups of at least 12 patients until unacceptable toxicity was reached. Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration. McDonald's criteria were used to evaluate antitumor activity. RESULTS: Seventy patients with brain tumors entered this study. The median number of prior chemotherapy treatments was two (range 1-3). Patients were assigned to one of four groups to receive temozolomide at daily doses of 200 (seven patients), 250 (13 patients), 300 (38 patients) and 350 mg/m(2)/day (12 patients). The absence of dose-limiting toxicity at cycle 1 led us to establish dose recommendations based on toxicity after repeated cycles. A total of 23, 72, 192 and 83 cycles were given at daily doses of 200, 250, 300 and 350 mg/m(2), respectively. Grade 3-4 thrombocytopenia was observed in 0/7, 1/13, 5/38 and 4/12 patients treated at doses of 200, 250, 300 and 350 mg/m(2)/day, respectively. Grade 3-4 neutropenia was observed in 1/7, 0/13, 3/38 and 4/12 patients treated with 200, 250, 300 and 350 mg/m(2)/day temozolomide, respectively. At a dose of 350 mg/m(2), sustained grade 2-3 thrombocytopenia did not allow treatment to be resumed at day 14 in >40% of patients, and this dose was considered to be the maximum tolerated dose. Thus, a dose of 300 mg/m(2)/day that was associated with <20% treatment delay due to sustained hematological toxicity was considered as the recommended dose. Objective responses were reported in 13 patients. CONCLUSIONS: Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors. 相似文献